Gemcitabine Plus Platinum Chemotherapy Compared with Other Platinum Containing Regimens in Advanced Non-small-cell Lung Cancer: a Meta-analysis of Survival Outcomes

OBJECTIVE To evaluate the treatment effect of gemcitabine plus platinum agent and compare the combination to vinorelbine or paclitaxel as ?rst-line regimens for advanced non-small-cell lung cancer(NSCLC). METHODS Published data from PubMed, CNKI was collected and investigated. The Cochrane Collaboration’s software RevMan 5.0 was used for meta-analyses. RESULTS Data from 23 randomized trials(8 from abroad, 15 from domestic) were included in a meta-analysis of time-to-event outcomes. Equivalent effective rata, higher 1-year survival rate from overseas data(P=0.03, 95%CI=1.03-1.84) and lower Ⅲ-Ⅳ leucocytopenia rate( P <0.01, 95%CI=0.33-0.54) in GP regimens were observed compared with NP regimens. There was no statistical difference( P =0.66, P =0.11) on efficacy and a significant difference on toxicity between GP regimens and TP regimens. CONCLUSION The differences of rates can possible cause different effect for patients treated by containing platinum regimens, should be an important factor when our country’s doctor choose regimen.